AUB ScholarWorks

Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer

Show simple item record

dc.contributor.author Farhat M.H.
dc.contributor.author El-Saghir N.S.
dc.contributor.author Shamseddine A.I.
dc.contributor.editor
dc.date Feb-2009
dc.date.accessioned 2017-10-05T15:39:18Z
dc.date.available 2017-10-05T15:39:18Z
dc.date.issued 2009
dc.identifier 10.1016/j.breast.2008.09.007
dc.identifier.isbn
dc.identifier.issn 09609776
dc.identifier.uri http://hdl.handle.net/10938/16798
dc.description.abstract Antiangiogenic therapy is a valuable new approach in the treatment of breast cancer. Response rates ranging from 6.7percent to 54percent were reported using Bevacizumab (AvastinR), anti-vascular endothelial growth factor, with chemotherapy. We report the first case of a patient, with a highly vascular breast cancer that recurred locally while on treatment with paclitaxel and trastuzumab combination, but showed complete clinical and pathological regression upon the addition of bevacizumab therapy to the same combination. © 2008 Elsevier Ltd. All rights reserved.
dc.format.extent
dc.format.extent Pages: (66-68)
dc.language English
dc.publisher EDINBURGH
dc.relation.ispartof Publication Name: Breast; Publication Year: 2009; Volume: 18; no. 1; Pages: (66-68);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer
dc.type Article
dc.contributor.affiliation Farhat, M.H., American University of Beirut-Medical center, Internal medicine-Division of Hematology-Oncology, P.O. Box: 11-0236-E21-Tumor registry, Riad El - Solh 11070720, Beirut, Lebanon
dc.contributor.affiliation El-Saghir, N.S., American University of Beirut-Medical center, Internal medicine-Division of Hematology-Oncology, P.O. Box: 11-0236-E21-Tumor registry, Riad El - Solh 11070720, Beirut, Lebanon
dc.contributor.affiliation Shamseddine, A.I., American University of Beirut-Medical center, Internal medicine-Division of Hematology-Oncology, P.O. Box: 11-0236-E21-Tumor registry, Riad El - Solh 11070720, Beirut, Lebanon
dc.contributor.authorAddress Shamseddine, A.I.; American University of Beirut-Medical center, Internal medicine-Division of Hematology-Oncology, P.O. Box: 11-0236-E21-Tumor registry, Riad El - Solh 11070720, Beirut, Lebanon; email: as04@aub.edu.lb
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; Division: Hematology-Oncology;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorDivision Hematology-Oncology
dc.contributor.authorEmail bellanotchi@hotmail.com; elsaghir@cyberia.net.lb; as04@aub.edu.lb
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Farhat, MH
dc.contributor.authorInitials El-Saghir, NS
dc.contributor.authorInitials Shamseddine, AI
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Shamseddine, AI (reprint author), Amer Univ Beirut, Med Ctr, Internal Med Div Hematol Oncol, POB 11-0236,E21 Tumor Registry,Riad El Solh 11070, Beirut, Lebanon.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Cobleigh MA, 2003, SEMIN ONCOL, V30, P117, DOI 10.1053-S0093-7754(03)00446-9; de Castro G, 2006, CRIT REV ONCOL HEMAT, V59, P40, DOI 10.1016-j.critrevonc.2006.02.007; du Manoir JM, 2006, CLIN CANCER RES, V12, P904, DOI 10.1158-1078-0432.CCR-05-1109; Epstein M, 2002, BREAST CANCER RES TR, V76, pS143; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007-BF00666035; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016-0092-8674(94)90187-2; FOLKMAN J, 1990, J NATL CANCER I, V82, P4, DOI 10.1093-jnci-82.1.4; Konecny GE, 2004, CLIN CANCER RES, V10, P1706, DOI 10.1158-1078-0432.CCR-0951-3; Miller KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200-JCO.2005.05.098; Otrock ZK, 2007, BLOOD CELL MOL DIS, V38, P258, DOI 10.1016-j.bcmd.2006.12.003; PEGRAM M, 2006, 29 ANN SAN ANT BREAS; Pegram MD, 2002, SEMIN ONCOL, V29, P29, DOI 10.1053-sonc.2002.34053; Ramaswamy B, 2006, CLIN CANCER RES, V12, P3124, DOI 10.1158-1078-0432.CCR.05-2603; Wedam SB, 2006, J CLIN ONCOL, V24, P769, DOI 10.1200-JCO.2005.03.4645; Yen L, 2000, ONCOGENE, V19, P3460, DOI 10.1038-sj.onc.1203685
dc.description.citedCount 2
dc.description.citedTotWOSCount 2
dc.description.citedWOSCount 2
dc.format.extentCount 3
dc.identifier.articleNo
dc.identifier.coden BREAE
dc.identifier.pubmedID 19013064
dc.identifier.scopusID 59949090933
dc.identifier.url
dc.publisher.address JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Breast
dc.relation.ispartOfIssue 1
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Breast
dc.relation.ispartofPubTitleAbbr Breast
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 18
dc.source.ID WOS:000264432700013
dc.type.publication Journal
dc.subject.otherAuthKeyword Bevacizumab
dc.subject.otherAuthKeyword Breast cancer
dc.subject.otherAuthKeyword Resistance
dc.subject.otherAuthKeyword Trastuzumab
dc.subject.otherChemCAS bevacizumab, 216974-75-3
dc.subject.otherChemCAS carboplatin, 41575-94-4
dc.subject.otherChemCAS cisplatin, 15663-27-1, 26035-31-4, 96081-74-2
dc.subject.otherChemCAS cyclophosphamide, 50-18-0
dc.subject.otherChemCAS docetaxel, 114977-28-5
dc.subject.otherChemCAS doxorubicin, 23214-92-8, 25316-40-9
dc.subject.otherChemCAS epidermal growth factor receptor 2, 137632-09-8
dc.subject.otherChemCAS fluorouracil, 51-21-8
dc.subject.otherChemCAS navelbine, 71486-22-1
dc.subject.otherChemCAS paclitaxel, 33069-62-4
dc.subject.otherChemCAS trastuzumab, 180288-69-1
dc.subject.otherChemCAS Angiogenesis Inhibitors
dc.subject.otherChemCAS Antibodies, Monoclonal
dc.subject.otherChemCAS Antineoplastic Agents, Phytogenic
dc.subject.otherChemCAS Paclitaxel, 33069-62-4
dc.subject.otherChemCAS bevacizumab
dc.subject.otherChemCAS trastuzumab
dc.subject.otherIndex bevacizumab
dc.subject.otherIndex carboplatin
dc.subject.otherIndex cisplatin
dc.subject.otherIndex cyclophosphamide
dc.subject.otherIndex docetaxel
dc.subject.otherIndex doxorubicin
dc.subject.otherIndex epidermal growth factor receptor 2
dc.subject.otherIndex fluorouracil
dc.subject.otherIndex navelbine
dc.subject.otherIndex paclitaxel
dc.subject.otherIndex trastuzumab
dc.subject.otherIndex adjuvant therapy
dc.subject.otherIndex adult
dc.subject.otherIndex advanced cancer
dc.subject.otherIndex article
dc.subject.otherIndex breast cancer
dc.subject.otherIndex cancer combination chemotherapy
dc.subject.otherIndex cancer grading
dc.subject.otherIndex cancer radiotherapy
dc.subject.otherIndex cancer regression
dc.subject.otherIndex cancer staging
dc.subject.otherIndex case report
dc.subject.otherIndex drug substitution
dc.subject.otherIndex drug withdrawal
dc.subject.otherIndex female
dc.subject.otherIndex follow up
dc.subject.otherIndex gene overexpression
dc.subject.otherIndex histopathology
dc.subject.otherIndex human
dc.subject.otherIndex lymph node metastasis
dc.subject.otherIndex mastectomy
dc.subject.otherIndex multiple cycle treatment
dc.subject.otherIndex priority journal
dc.subject.otherIndex punch biopsy
dc.subject.otherIndex recurrent cancer
dc.subject.otherIndex skin biopsy
dc.subject.otherIndex skin metastasis
dc.subject.otherIndex skin surgery
dc.subject.otherIndex thorax wall
dc.subject.otherIndex treatment response
dc.subject.otherIndex Angiogenesis Inhibitors
dc.subject.otherIndex Antibodies, Monoclonal
dc.subject.otherIndex Antineoplastic Agents, Phytogenic
dc.subject.otherIndex Antineoplastic Combined Chemotherapy Protocols
dc.subject.otherIndex Breast Neoplasms
dc.subject.otherIndex Carcinoma, Ductal, Breast
dc.subject.otherIndex Chemotherapy, Adjuvant
dc.subject.otherIndex Female
dc.subject.otherIndex Humans
dc.subject.otherIndex Mastectomy, Modified Radical
dc.subject.otherIndex Middle Aged
dc.subject.otherIndex Neoplasm Recurrence, Local
dc.subject.otherIndex Paclitaxel
dc.subject.otherKeywordPlus ENDOTHELIAL GROWTH-FACTOR
dc.subject.otherKeywordPlus ANGIOGENESIS
dc.subject.otherKeywordPlus TRIAL
dc.subject.otherKeywordPlus XENOGRAFTS
dc.subject.otherKeywordPlus THERAPY
dc.subject.otherWOS Oncology
dc.subject.otherWOS Obstetrics and Gynecology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account